Francisco Talavera, PharmD, PhD

Francisco Talavera, PharmD, PhD, obtained his doctorate in science from Washington State University and pursued a postdoctoral fellowship in endocrinology and cancer research at the University of Michigan under a National Research Award from the National Cancer institute. He has published 17 studies in peer-reviewed journals. He then went on to earn his Doctor of Pharmacy degree from Creighton University. For the past 26 years he has worked as a managing editor for the Drug Reference at Medscape.

Recent WebMD content from Francisco Talavera, PharmD, PhD

FDA Approves Hovilpri for Hard-to-Treat Herpes Lesions in People With Weak Immune Systems
FDA Approves Atebrioz to Reduce Extra Bone Growth in Rare Gene Disorder
FDA Approves Lyrfigtu for Advanced Bile Duct Cancer
FDA Approves Joenja for Younger Children With Rare Immune Disease
FDA Approves Etcamah Combination for Advanced Breast Cancer
FDA Approves Zanvastro for Rare Brain Disorder Alexander Disease
FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia
FDA Approves Ziihera Combinations for Advanced Stomach and Esophageal Cancers
FDA Approves Zenbexus Combination for Multiple Myeloma
FDA Approves Tudriqev for Advanced Skin Cancer
FDA Approves mFlusiva, the First mRNA Flu Vaccine for Older Adults
Headline: FDA Approves Gwyn Lo, a New Low-Dose Weekly Birth Control Patch
Skyrizi: FDA Approves Pediatric Expansion of IL‑23 Inhibitor for Moderate-to-Severe Plaque Psoriasis and Active Psoriatic Arthritis
Lumvoa: FDA Approves New Intravenous Treatment for Both Active and Chronic Thyroid Eye Disease
Trodelvy (sacituzumab govitecan-hziy): First-Line Treatment for Triple-Negative Breast Cancer and an Antibody-Drug Conjugate Option for Certain Advanced Breast Cancers
Capvaxive: 21-Valent Pneumococcal Conjugate Vaccine Adds Broader Strain Coverage and a New FDA Indication for High-Risk Children and Teens
Utebzi: First oral carbapenem for complicated urinary tract infections in adults
Hympavzi: Once‑Weekly, Single‑Dose Under‑the‑Skin Shot to Help Prevent Bleeding in Hemophilia A or B (ages 6+)
Xocova: FDA Approves First Oral Post-Exposure Prophylaxis to Help Prevent COVID-19 in Adults and Adolescents 12 and Older
Afrezza: FDA Clears Use for Children 6 and Older With Type 1 or Type 2 Diabetes
Datroway: FDA Approves Antibody-Drug Conjugate Injection for Advanced Triple-Negative Breast Cancer
Tecentriq and Tecentriq Hybreza: FDA Approves First ctDNA‑Guided Adjuvant Immunotherapies to Target Residual Muscle‑Invasive Bladder Cancer After Surgery
Enhertu: FDA Clears New Pre- and Post-Surgery Uses in HER2-Positive Early Breast Cancer
Beqalzi: FDA Approves New Oral BCL-2 Blocker for Relapsed or Refractory Mantle Cell Lymphoma
Bizengri: FDA Approves Second-Line Intravenous Treatment for Adults With NRG1 Fusion-Positive, Advanced, Surgically Unresectable, Metastatic Bile Duct Cancer
Veppanu (Vepdegestrant): An Oral Protein Degrader for Certain ER+/HER2- Advanced Breast Cancers
FDA Expands Auvelity Use for Agitation in Alzheimer’s Dementia
Caplyta (Lumateperone): FDA Updates Labeling for Once-Daily Antipsychotic to Help Prevent Relapse in Patients With Schizophrenia
Awiqli: FDA Approves First and Only Once-Weekly Long-Acting Basal Insulin for Adults With Type 2 Diabetes
Kresladi: FDA Approves First One-Time Gene Therapy for Children With Severe Leukocyte Adhesion Deficiency Type I

1 of 3

Francisco Talavera, PharmD, PhD

Top doctors in ,

Find more top doctors on